CRi Launches the TRIO™ Multispectral Imaging System for Multi-Analyte Investigation in Tissue

WOBURN, Mass., Nov. 9, 2010 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi), a leader in multicolor imaging solutions for preclinical and clinical research, today announced the newest addition to the award-winning Nuance™ multispectral imaging product family for multicolor tissue and cell-based imaging. The TRIO system is compact, multipurpose and affordable, offering a simplified interface and versatile design to fit any microscope with a camera-mount. This newest offering strengthens CRi's objective to offer a comprehensive and intuitive solution that enables customers from basic research through pre-clinical drug discovery to reveal correlations between protein expression in intact tissue and clinical outcomes.

(Photo: http://photos.prnewswire.com/prnh/20101109/NE97171 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20101109/NE97171 )

Multi-analyte detection from intact tissue and cells often poses a challenge since overlapping signals and the sample's own background autofluorescence can mask critical information. TRIO's multispectral imaging technology found in all of CRi's multispectral systems effectively unmixes overlapping labels in fluorescence or brightfield samples. It has a new easy-to-use software interface designed to preclude the need to have expert-level knowledge of multispectral imaging, a common hurdle that faces many scientists who want to be able to image multiple markers from a single tissue sample. TRIO's interface ensures that data can be obtained in a matter of minutes.

"Detecting multiple markers in intact tissue sections and in individual tumor cells is an important component of targeted drug and molecular diagnostic development," said Darren Lee, Vice President of Marketing at CRi.  "We understand the hurdles associated with doing multilabel imaging, including the complexities of interpreting multispectral data. We are very excited about TRIO because it makes multicolor imaging of tissue and cells much easier and more accessible to the mainstream researcher." Lee added, "TRIO fits nicely within our core strategies, providing solutions that help address one of the biggest challenges facing scientists: trying to understand the mechanisms behind disease."

About CRi, Inc.

Cambridge Research & Instrumentation (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi's patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi's products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi's award-winning systems include Nuance™ and TRIO™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging.  Learn more at www.cri-inc.com.

SOURCE Cambridge Research & Instrumentation, Inc.